ConductScience.org, home

Paper38612640

Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.

Chrysavgis LG and 5 others. Int J Mol Sci, 2024. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. Papers, record 38612640. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38612640

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
3.6, provisional
iCite
Revised in PubMed
2026-01-27
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chrysavgis LGLampros Ghttps://orcid.org/0000-0003-2632-0742
2Kazanas SSpyridonhttps://orcid.org/0000-0003-3819-2661
3Bafa KKonstantina
4Rozani SSophiahttps://orcid.org/0000-0002-4465-022X
5Koloutsou MEMaria-Evangelia
6Cholongitas EEvangeloshttps://orcid.org/0000-0002-3645-582X

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Fatty LiverMajor topic
Liver DiseasesMajor topic
Metabolic DiseasesMajor topic
Humans
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
Incretins
Receptors, G-Protein-Coupled
Receptors, Glucagon

Source PubMed

Download CSV of topics

References143

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132952876Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.World J Hepatol2020https://conductscience.org/library/papers/32952876PubMed
218292967Glucagon receptors.Cell Mol Life Sci2008https://conductscience.org/library/papers/18292967PubMed
337758044
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Am Heart J2024https://conductscience.org/library/papers/37758044PubMed
432696080NAFLD and cardiovascular diseases: a clinical review.Clin Res Cardiol2021https://conductscience.org/library/papers/32696080PubMed
530359962Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).Pharmacol Res2018https://conductscience.org/library/papers/30359962PubMed
637379656Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice.EBioMedicine2023https://conductscience.org/library/papers/37379656PubMed
734570916Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.Aliment Pharmacol Ther2021https://conductscience.org/library/papers/34570916PubMed
832059982NAFLD as a driver of chronic kidney disease.J Hepatol2020https://conductscience.org/library/papers/32059982PubMed
925053587Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.Diabetes2015https://conductscience.org/library/papers/25053587PubMed
1037364790A multisociety Delphi consensus statement on new fatty liver disease nomenclature.J Hepatol2023https://conductscience.org/library/papers/37364790PubMed
1132196896Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.Diabetes Obes Metab2020https://conductscience.org/library/papers/32196896PubMed
1228648835Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.Diabetes Metab2017https://conductscience.org/library/papers/28648835PubMed
1319141695
Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver.
Am J Clin Nutr2009https://conductscience.org/library/papers/19141695PubMed
1436626630The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023https://conductscience.org/library/papers/36626630PubMed
1532478287Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.Nat Metab2020https://conductscience.org/library/papers/32478287PubMed
1638095657
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia2024https://conductscience.org/library/papers/38095657PubMed
1737103096Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.In Vivo2023https://conductscience.org/library/papers/37103096PubMed
1831671603Glucagon Regulation of Energy Expenditure.Int J Mol Sci2019https://conductscience.org/library/papers/31671603PubMed
1918723001Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice.Biochem Biophys Res Commun2008https://conductscience.org/library/papers/18723001PubMed
2037149203Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.Semin Cancer Biol2023https://conductscience.org/library/papers/37149203PubMed

See all 143 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
42387035Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.Endocrine2026https://conductscience.org/library/papers/42387035PubMed
42278284Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.Int J Mol Sci2026https://conductscience.org/library/papers/42278284PubMed
42078303
Glucagon-Like Peptide-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric Metabolic Dysfunction-Associated Liver Disease Cohort and Normalize Disease-Associated Core Gene Expression in an Experimental Model.
Cureus2026https://conductscience.org/library/papers/42078303PubMed
41715264Emerging therapeutic regimens as alternatives to glucocorticoids for severe alcohol-associated hepatitis: a comprehensive review.Clin Mol Hepatol2026https://conductscience.org/library/papers/41715264PubMed
41465555The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.Int J Mol Sci2025https://conductscience.org/library/papers/41465555PubMed
41266634Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice.Sci Rep2025https://conductscience.org/library/papers/41266634PubMed
41231418AI-Based Models for Risk Prediction in MASLD: A Systematic Review.Dig Dis Sci2026https://conductscience.org/library/papers/41231418PubMed
40938549Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.Cardiovasc Drugs Ther2026https://conductscience.org/library/papers/40938549PubMed
40937349GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.Front Clin Diabetes Healthc2025https://conductscience.org/library/papers/40937349PubMed
40751781Sex and gender differences in metabolic dysfunction-associated liver disease.Indian J Gastroenterol2026https://conductscience.org/library/papers/40751781PubMed
40722592Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?Biomedicines2025https://conductscience.org/library/papers/40722592PubMed
40391051The Therapeutic Effect and Mechanism of Traditional Chinese Medicine in Type 2 Diabetes Mellitus and Its Complications.Diabetes Metab Syndr Obes2025https://conductscience.org/library/papers/40391051PubMed
39200096Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions.Biomedicines2024https://conductscience.org/library/papers/39200096PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
GCGR2642PubTator's text mininghttps://conductscience.org/library/genes/2642NCBI Gene
GIP2695PubTator's text mininghttps://conductscience.org/library/genes/2695NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38612640

GET https://conductscience.org/api/papers/v1/38612640/references?page=2